Skip to main content

Miller Fisher syndrome: a diagnosis not to be missed

  • S J Davis (a1), R Salib (a1), H Buchan (a2) and E Nilssen (a1)

We report a case of Miller Fisher syndrome presenting in an ENT setting. The referral was made on the basis of worsening nasal regurgitation following Campylobacter jejuni enteritis. The aim of this report is not to add to the recorded instances of Miller Fisher syndrome, but to help raise the level of its awareness amongst otolaryngologists. Emphasis is placed on the mode of presentation and management issues, as early diagnosis is crucial and confers a favourable prognosis. In that respect, we consider this case noteworthy and instructive.

Corresponding author
Address for correspondence: Mr S J Davis, 106 Nibley Road, Shirehampton, Bristol BS11 9XW, UK. Fax: 0117 9595850 E-mail:
Hide All
1Fisher CM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:5765
2Overell JR, Willison HJ. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 2005;18:562–6
3Ito M, Odaka M, Koga M, Hirata K, Yuki N. Clinical features and treatment of Fisher syndrome [in Japanese]. Rinsho Shinkeigaku 2005;45:514–17
4Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32–6
5Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T et al. Molecular mimicry between GQ1b, ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791–3
6Koga M, Gilbert M, Li J, Koike S, Takahashi M, Furukawa K et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605–11
7Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J et al. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999;104:697708
8Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, Todd AJ et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 2004;127:2109–23
9O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001;124:893906
10Hughes RA, Cornblath DR. Guilain-Barre syndrome. Lancet 2005;366:1653–66
11Meythaler JM. Rehabilitation of Guillain-Barré syndrome. Arch Phys Med Rehabil 1997;78:872–9
12Guiloff RJ. Peripheral nerve conduction in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1977;40:801–7
13Fross RD, Daube J. Neuropathy in the Miller-Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987;37:1493–8
14Battaglia F. Recurrent Miller-Fisher syndrome. Rev Neurol (Paris) 2005;161:844–7
15The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096–104
16McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347–53
17French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298306
18Espérou H, Jars Guincestre MC, Bolgert F, Raphael JC, Durand-Zaleski I, French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Cost-effectiveness of plasma exchange therapy for the treatment of Guillain-Barré syndrome. Intensive Care Med 2000;26:1094–100
19Hughes RA, Raphael C, Swan AV, van Doom PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2001;2:CD002063
20Hughes RAC, Wijdicks E, Barohn RJ. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736–40
21Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367–75
22Korinthenberg R, Schessl J, Kirschner J, Montning JS. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome. Pediatrics 2005;116:226–8
23Farcas P, Avnun L, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997;350:1747
24Willison HJ, Townson K, Veitch J, Boffrey J, Issacs N, Andersen SM et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 2004;127:680–91
25Hughes RAC, van der Meche FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev 2000;2:CD001446
26Rich MM, Pinter MJ, Craner SD, Barchi RL. Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998;43:171–9
27Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 2003;61:1282–4
28Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005;128:1828
29Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doom PA. Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 1999;53:1648–54
30Bernsen AJAM, De Jager AEJ, Schmitz PIM, van der Meché FGA. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci 2002;201:1317
31Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. BMJ 1951;2:7781
32Odaka M, Yuki N, Yamada M, Koga M, Tagemi T, Hirata K et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003;126:2279–90
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The Journal of Laryngology & Otology
  • ISSN: 0022-2151
  • EISSN: 1748-5460
  • URL: /core/journals/journal-of-laryngology-and-otology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 1
Total number of PDF views: 7 *
Loading metrics...

Abstract views

Total abstract views: 84 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st November 2017. This data will be updated every 24 hours.